About Joseph McCoy

Commercial Judgment Before Capital Is Committed

Biotechnology companies make some of their most consequential commercial decisions years before launch.

An indication is selected. A clinical program is funded. A market forecast is accepted. Capital and organizational resources are committed.

But the central question may remain unanswered:

I founded PharmaKonsult to help biotechnology CEOs, boards and investors answer that question before expensive decisions become difficult to reverse.

Working Backward from Commercial Success

PharmaKonsult begins with the outcome the company must ultimately achieve: a clinically meaningful product that reaches the right patients and generates sufficient value to justify the investment.

I work backward from that outcome through the decisions and operating requirements necessary to achieve it. I then test the proposed strategy forward to determine whether the development plan can realistically produce the intended commercial result.

The assessment connects four critical areas:

• Portfolio and development strategy
• Patient and market feasibility
• Reimbursement and commercial viability
• Capital allocation and implementation

These areas cannot be evaluated independently.

A product may succeed clinically but fail commercially if patients cannot be identified, physicians cannot be reached, payers will not support the required reimbursement or the operating model costs more than the opportunity can justify.

Likewise, an attractive market forecast has little value if the clinical program is too expensive, too slow or unable to recruit the necessary patients.

The objective is to determine whether the entire pathway connects—from indication selection and clinical development through patient access, commercialization and investment recovery.

Experience Across the Details That Determine Product Success

My perspective was developed over more than three decades inside pharmaceutical and biotechnology companies.

I have been responsible for the details that determine whether a product succeeds after the strategy is approved: identifying the right patients and physicians, securing account access, navigating reimbursement, allocating field resources, establishing sales accountability, developing leaders and converting plans into measurable performance.

That experience includes:

• 30+ years in pharmaceutical and biotechnology commercial leadership
• 20+ product launches
• Leadership across rare disease, specialty neurology, institutional markets and market access
• Ten-time Pinnacle Club recognition, including eight awards as a leader
• #1 national launch performance during the introduction of XCOPRI
• Development of more than two dozen future managers
• Service as a U.S. Navy officer responsible for people, operations and resources

My credentials are grounded in more than commercial performance. They come from repeated responsibility for connecting product strategy with the details that ultimately determine success—patient identification, physician adoption, reimbursement, institutional access, resource allocation, sales accountability, leadership and execution.

That operating experience allows me to evaluate development and investment decisions from a perspective that is often missing early in biotechnology:

Commercial and Scientific Perspective

PharmaKonsult’s role is intentionally commercial, operational and financial.

I evaluate whether the clinical strategy, market opportunity, reimbursement pathway, organizational requirements and capital investment can connect to create a viable product and company value.

When specialized clinical perspective is required, PharmaKonsult is supported by independent scientific advisors with expertise across neurology, rare disease and clinical development.

The objective is not to replace scientific expertise. It is to ensure that scientific promise is connected to commercial reality.

Applied to Real Biotech Decisions

PharmaKonsult case studies demonstrate how commercial judgment can shape product development, launch execution and investment decisions.

They include examples of overcoming institutional access barriers, converting reimbursement changes into commercial growth, leading a nationally successful product launch and evaluating whether proposed biotechnology investments can produce commercially viable products.

Each case demonstrates the same principle:

Better Decisions Before Expensive Mistakes

I do not begin with the assumption that management’s current strategy is wrong—or that it is right.

I begin with the evidence, challenge the assumptions and determine whether the proposed pathway can realistically produce the outcome the company expects.

Sometimes the right decision is to accelerate.

Sometimes it is to change the indication, evidence plan, commercial model or partnership strategy.

Sometimes the most valuable recommendation is to stop investing in an opportunity that no longer justifies the capital.